• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

2.175 +0.025 (+1.16%)
Streaming Delayed Price Updated: 12:18 PM EDT, Jun 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 22, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Where Fate Therapeutics Stands With Analysts ↗
April 11, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
April 10, 2024
 
Via Benzinga
News headline image
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts ↗
March 19, 2024
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics ↗
February 27, 2024
 
Via Benzinga
News headline image
Recap: Fate Therapeutics Q4 Earnings ↗
February 26, 2024
 
Via Benzinga
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 19, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Preview Of Fate Therapeutics's Earnings ↗
February 23, 2024
 
Via Benzinga
News headline image
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 01, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
February 27, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Fate Therapeutics ↗
November 09, 2023
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2024 ↗
February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
News headline image
Recap: Fate Therapeutics Q3 Earnings ↗
November 08, 2023
 
Via Benzinga
Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18
September 18, 2023
Via Investor Brand Network
News headline image
Analyst Ratings for Fate Therapeutics ↗
September 07, 2023
 
Via Benzinga
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock ↗
January 29, 2024
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. 
Via InvestorPlace
News headline image
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
January 08, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
January 03, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... 
Via Benzinga
Topics Stocks
News headline image
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2023
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
December 12, 2023
 
Via Benzinga
News headline image
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 08, 2023
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 03, 2023
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
October 25, 2023
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Present at Upcoming September Investor Conferences
August 31, 2023
From Fate Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap